Vivani Medical, Inc. · NASDAQ:VANI
Vivani Medical — Second Sight Medical Products — Investor Presentation (September 2017)
23 slides from Vivani Medical's investor presentation, Sep 12, 2017
Slide 1: Enriching the lives of the blind
NASDAQ: EYES Enriching the lives of the blind September 2017
Slide 2: Forward Looking Statements
Forward Looking Statements This contains certain fe ‘d-looking inform: about Second Sight that is intended to be covered by the safe harbor for "forward-looking statements” provided by the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that ar
Slide 3: Second Sight Medical Products, Inc.
NASDAQ: EYES Second Sight Medical Products, Inc. We have created an implantable prosthesis that enables useful
Slide 4: Restoring Vision With Neurostimulation
Restoring Vision With Neurostimulation Worlds First Bionic Eye * Neurostimulation platform * Addresses multiple forms of blindness Demonstrated clinical benefit 410+ issued patents Regulatory | favorably Currently Available + Regulatory clearance in U.S., E.U. & other key markets * 250+ patients tre
Slide 5: Video: Bionic Eye Gives Sight to
Video: Bionic Eye Gives Sight to VIRING THE WORLD
Slide 6: End-Stage Retinitis Pigmentosa (<0.2M)
End-Stage Retinitis Pigmentosa (<0.2M) Bare light or no light perception (completely blind) ‘Argus I” commercially available Legally Blind RP Population Broader population with less vision loss Next-gen Argus platform: software changes ‘Age-Related Macular Degeneration oS (amp) + Clinical trial in d
Slide 7: ARGUS II Technology
ARGUS II Technology NASDAQ: EYES Functional vision restored by bypassing the damaged part of the retina to send visual signals to the healthy retinal cells Transmitter; Camera « Qs Electrodes Optic nerve Using a camera housed in a patient's glasses, images are collected and converted into a series o
Slide 8: Orion Technology — Our Next Generation
NASDAQ: EYES Orion Technology — Our Next Generation Breakthrough Orion platform bypasses the damaged eye and/or optic - nerve to send visual signals directly to the brain The Orion is built on the Argus I! platform leveraging decades of research e Camera housed in a patient's glasses collects images
Slide 9: Chronic Visual Cortical Stimulation using "Off the Shelf" Device
Chronic Visual Cortical Stimulation using NASDAQ: EYES “Off the Shelf” Device Second Sight sponsored a clinical trial at UCLA which was announced Q4 2016 * 30 year old with an 8 year history of bare light perception blindness Methods: ion of a Neurosti device with 2 parallel 4-contact leads implante
Slide 10: Stimulation Thresholds Are Stable Over Months
NASDAQ: EYES Stimulation Thresholds Are Stable Over 7 Months ° 2 ° 0 wm °o 0 wm 0 00 Frequency (He) cat cz cz cm 4 4 4 4 3 3 3 ale ate 2 . aoe e 2 . . ° ry wm = °O ry mo “o rn wm % 00 Second Sight. 10
Slide 11: FDA has approved clinical trial
FDA has approved i Up to 5 bare light perception blind patients in 2 centers * UCLA- University of California - LA + Baylor College of Medicine, Houston A third center is planned in Europe pending European Regulatory Approval. Feasibility Study with multiple safety and utility endpoints. The FDA has
Slide 12: Established Technology Leadership
NASDAQ: EYES Established Technology Leadership Pioneering Technology Groundbreaking Research Recognized Leadership °: = Frau saley and Perfomance Rate Saat ‘inion ote a £3 cleveland Clinic. ip dc oan 018 WORLD ECONOMIC ’ 50 SMARTEST ¥ FOROS | EES companies # ‘Technology Peneer 2014 "Tee 30 Smartest
Slide 13: Established Technology Leadership
Established Technology Leadership ‘CUMULATIVE TOTAL COMMERCIAL IMPLANTS BY QUARTER AND BY YEAR [EX RE-COMMERCIAL IMPLANTS} Second Sight.
Slide 14: Significant first mover advantage
in ae Significant first mover advantage — Currently the only Retinal Prosthesis Competitors CE Mark Second Sight, Argus®Il Retina implant (Germany) Pixium Vision (France) Nidek Co., Ltd. (Japan) Bionic Vision Technologies (Australia) NanoRetina (Israel) Stem Cells Gene Therapy Opto-Genetics Transpla
Slide 15: Expanding Reimbursement Coverage
Expanding Reimbursement Coverage Achievements-to-Date 7 of 12 MAC* jurisdictions (~62% of US population) with positive coverage decision Attained new CPT codes for initial programming and reprogramming of Argus Il $150k reimbursement rate set for 2017 Coverage in England under “Commissioning through
Slide 16: 2017 Key Strategic Objectives
2017 Key Strategic Objectives NASDAQ: EYES Building a Foundation for Long-Term Growth £. Validate revised Centers of Excellence commercial model in U.S. in order to drive adoption Demonstrate the ability to treat better-sighted RP. patients in order to expand our treatable population beyond end stag
Slide 17: Partner with leading medical institutions to establish a network of surgical centers
Partner with leading medical institutions to establish a network of high-quality surgical centers that are capable of treating a higher volume of patients + Full reimbursement for all device & procedure costs of '$150K in 2017. Prelim rate in 2018 of $122k. + Focused regional patient outreach + Upgr
Slide 18: Treating Better-Sighted Patients
Treating Better-Sighted Patients v Argus Il Enhancements : Clinical Testing Clinical Testing of Current of Argus II Argus II Enhancements Technology in in Better- Better-Sighted Sighted RP & RP Patients AMD Patients Second Sight.
Slide 19: Expanding into Potential 5.8M Market with Orion
Expanding into Potential 5.8M P. Market with Orion Leverage existing Argus II technology Bypass the optic nerve and directly stimulate the visual cortex First in human feasibility assessment complete (n=1) with positive outcomes Begin US feasibility study in second half 2017 30 year old female patie
Slide 20: Select Financials
NASDAQ: EYES Select Financials Implants Revenue $2,236 $1,037 $3,985 $8,950 Gross Profit (Loss) 1,109 (2,204) (6,091) 3,657 Net Loss (6,843) (8,504) (33,179) (20,018) Non-GAAP Adjusted Net Loss* (6,586) (6,197) (24,812) (17,007) a Cash, cash equivalents & investments $18,129 $10,875 $15,960 Outstand
Slide 21: Improved Orientation and Mobility
Improved Significant Orientation and Improvement in Mobility Enhanced Connection to Loved Ones Greater Independence Second Sight
Slide 22: Second Sight Investment Highlights
NASDAQ: EYES Second Sight Investment Highlights Technology Leadership * — First and only treatment approved for sale in the US, EU, Saudi Arabia, Turkey and Canada * Robust IP portfolio with 500+ patents issued and pending; Over $200M invested to date + Significant first mover advantage with 5+ year
Slide 23: Contacts
NASDAQ: EYES Contacts Second Sight Medical Products, Inc. 12744 San Fernando Road Suite 400 Sylmar, CA 91342 Main: 818-833-5000 www.secondsight.com Robert Greenberg MD, PhD. Chairman Direct: 818-833-5050 bob@secondsight.com Retail Investor Relations Institutional Investor Relations Greg Falesnik Lis
Second Sight Medical Products — Investor Presentation (September 2017) on 6ix